Results 31 to 40 of about 304,324 (330)
The significance of M1/M2 macrophage-like monocytes in children with systemic lupus erythematosus
European Journal of Inflammation, 2019 Monocytes/macrophages are important in the development of systemic lupus erythematosus. To research M1 and M2 macrophage-like monocytes in the peripheral blood of children with systemic lupus erythematosus and explore the clinical significance, M1 and M2
Xiao-Ling Niu +6 more
doaj +1 more source
Clinics, 2015 OBJECTIVES: To determine the serum interleukin-17 (IL-17) levels in childhood-onset systemic lupus erythematosus patients and to evaluate the association between IL-17 and clinical manifestations, disease activity, laboratory findings and treatment ...
Karina de Oliveira Peliçari +7 more
doaj +1 more source
Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects [PDF]
Anais Brasileiros de Dermatologia, 2014 Systemic Lupus Erythematosus is a chronic inflammatory disease with multifactorial etiology. Although clinical manifestations are varied, the skin is an important target-organ, which contributes to the inclusion of skin lesions in 4 out of the 17 new ...
Jucelio Pereira Moura Filho +6 more
doaj +1 more source
Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
Rheumatology and Therapy, 2020 Despite recent improvements in the treatment of systemic lupus erythematosus (SLE), disease activity, comorbidities and drug toxicity significantly contribute to the risk of progressive irreversible damage accrual and increased mortality in patients with
F. Basta +3 more
semanticscholar +1 more source
BMC Musculoskeletal Disorders, 2004 Background Systemic lupus erythematosus is an age- and gender-associated autoimmune disorder. Previous studies suggested that defects in the hypothalamic/pituitary axis contributed to systemic lupus erythematosus disease progression which could also ...
Malemud Charles J, Denko Charles W
doaj +1 more source
Arthritis & Rheumatology, 2017 To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate‐to‐severe systemic lupus erythematosus (SLE).
R. Furie +9 more
semanticscholar +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad +8 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li +10 more
wiley +1 more source
Case Reports in Nephrology and Dialysis, 2022 Renal involvement in systemic lupus erythematosus is usually exhibited as lupus nephritis, which is a form of immune complex-mediated glomerulonephritis and one of the most severe organ manifestations of systemic lupus erythematosus.
Chee Eng Chan +3 more
doaj +1 more source
Systemic lupus erythematosus [PDF]
BMJ, 2007 Systemic lupus erythematosus in pregnancy brings risks for the mother, and possible harm to the fetus if the disease is treated.
Sarah J Germain +2 more
openaire +3 more sources